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Abstract  
Immune checkpoint inhibitors are drugs that inhibit the “checkpoint molecules”. Different types of cancer immune 
checkpoint inhibitors have been approved recently: CTLA-4 monoclonal antibodies (as ipilimumab); anti-PD-1 monoclonal 
antibodies (as pembrolizumab and nivolumab); and anti-PD-L1 monoclonal antibodies (as atezolizumab, avelumab, and 
durmalumab). The increased immune response induced by these agents leads to immune-related adverse events (irAEs), that 
can vary from mild to fatal, according to the organ system and severity. Immune-related endocrine toxicities are thyroid 
dysfunctions, hypophysitis, adrenal insufficiency, and type 1 diabetes mellitus, and are usually irreversible in 50%. In 
particular, hypophysitis is the most frequent anti-CTLA-4-antibodies-related irAE, while thyroid abnormalities (as 
hypothyroidism, thyrotoxicosis, painless thyroiditis, or even “thyroid storm”) are more frequently associated with anti-PD-
1-antibodies. The combination of anti-CTLA-4-antibodies, with anti-PD-1-antibodies, is associated with about 30% of 
irAEs. Clinical signs and symptoms vary according to the influenced target organ. Endocrinopathies can often be managed 
by the treating oncologist. However in more severe cases (i.e. in the presence of insulin-dependent diabetes, adrenal 
insufficiency, or disorders of gonadal hormones, or severe hyperthyroidism, or hypothyroidism, or long-lasting management 
of hypophysitis) an endocrinological evaluation, and a prompt therapy, are needed. 
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1 Introduction 
In cancer immunotherapy the immune system is manipulated to treat cancer. Different types of cancer immunotherapies 
have been approved recently, as precautionary and therapeutic cancer vaccines [1], immune checkpoint inhibitors (ICI) [2, 
3], a bi-specific T-cell engager, and an oncolytic virus [4]. 
Other studies are evaluating the involvement of cytokines and chemokines, in human cancer, and their possible modulation 
[5-7]. 
The immune system recognizes and destroys foreign or tumor cells, through the antigens recognition by T-cells that 
involves the interaction of the major histocompatibility complex molecules, with the antigen presenting cells (APC).  
Cancer therapies lead cancer cells to die and release tumor antigens, presented by dendritic cells in the tumor-draining 
lymph nodes in order to activate tumor immunity. In this way, tumor-specific T cells enter the circulation towards tumors, 
infiltrating the tumor mass. Cancer cells lysis, mediated by T-cells, leads to a higher release of tumor antigens, perpetuating 
the cycle [8].  
Immune checkpoints regulate the immune system, and are determinant for self-tolerance, that prevents the immune system 
from attacking cells randomly. “Stimulatory checkpoint molecules” belong to the tumor necrosis factor (TNF) receptor 
superfamily (CD27, CD40, OX40, GITR and CD137), while others are members of the B7-CD28 superfamily (CD28 and 
ICOS); also different “inhibitory checkpoint molecules” exist, and among them CTLA-4 (Cytotoxic T-Lymphocyte-
Associated protein 4, known as CD152, whose expression on Treg cells serves to control T cell proliferation) is the target of 
Bristol-Myers Squibb's melanoma drug ipilimumab (Yervoy), approved by Food and Drug Administration (FDA) in March 
2011 [9], and PD-1 (Programmed Death 1 receptor; with the two ligands PD-L1 and PD-L2) is the target of Merck & Co.'s 
melanoma drug pembrolizumab (Keytruda), approved by FDA in September 2014 [10].  
Immune checkpoint inhibitors are drugs that inhibit the “inhibitory checkpoint molecules”. 
CTLA-4 is constitutively expressed by regulatory T cells and upregulated after T cells activation, acting as an "off" switch. 
CTLA-4 binds the B7 ligand on APC. Binding CTLA-4, ICI prevent it from binding with B7, and allow B7 to bind with 
CD28, in this way inducing the immune system to attack tumor cells [11]. 
PD-1 is present on T, B, and NK cells, and binds to PD-L1, expressed by tumor cells, preventing apoptosis of the cell 
expressing PD-L1 by the immune system. ICI, that bind either PD-L1 or PD-1, prevent this process [11]. 
FDA approved anti-CTLA-4 monoclonal antibodies (as ipilimumab), anti-PD-1 monoclonal antibodies (as pembrolizumab 
and nivolumab), and anti-PD-L1 monoclonal antibodies (as atezolizumab, avelumab, and durmalumab) [11]. 
Different characteristics of cancer immunotherapy with ICI have been reported [8, 12]: ICI involve T cells with innate 
capacity for adaptability and memory, underlying the long-lasting responses and survival reported with these therapies; ICI 
treat the immune system, despite either tumor histology or the absence/presence of driver mutations; the side effects 
associated with ICI are different from those of chemotherapy and targeted therapies; the effectiveness of immunotherapy 
can be ameliorated by the combination among ICI and other treatment strategies [8, 12].  
 
2 Cancer immunotherapy with ICI targets different tumor types  
Cancer immunotherapy has the immune system as target, for this reason its effectiveness is independent from tumor type, or 
the absence/presence of driver mutations.  
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For example ipilimumab has a long-lasting effect in mucosal, ocular, and cutaneous melanomas, that have different biology 
[13-18], and no differences were present between NRAS- and BRAF-mutated melanoma regarding the duration of response 
or overall survival (OS) [19]. Subgroup analyses conducted in the phase 3 trial MDX010-20 indicate ipilimumab has a 
survival long-lasting effect across patient populations, also in those subjects with a known poor prognosis (for example with 
poor performance status or raised lactate dehydrogenase) [12, 20]. Ipilimumab has also shown to have activity in old 
patients and those with stable asymptomatic brain metastases, supporting the hypothesis of a potential benefit with 
immunotherapy in wide patient populations [21, 22].   
Also the effectiveness of PD-1 blockade has been reported in multiple tumor types, as Hodgkin’s lymphoma, kidney cancer, 
esophageal and gastric cancers, small-cell lung cancer (SCLC), hepatocellular cancer, non-small-cell lung cancer (NSCLC), 
head and neck cancer, breast cancer, bladder cancer, and others [12]. In particular, PD-1 blockade is more efficacious in 
some cancer subtypes (i.e. the clinical activity is more promising in triple negative PD-L1+ breast cancer [23]). Therefore, 
long-term survival can be obtained in some patients across a range of distinct tumor types, in whom the different response 
rates denote different tumor immunogenicity. 
The activity of the anti-PD1 antibody nivolumab has been investigated in different tumor types. In  phase 1 trials [24, 25], 
median OS was 9.6 months, 16.8 months and >22 months, in patients with NSCLC, melanoma and renal cell carcinoma, 
respectively.  
Other ICI, as other anti-PD-1/PD-L1 agents, are also under evaluation in different solid tumors and haematological 
malignancies [12].  
 
3 ICI toxicities 
Checkpoint inhibitors have a different safety profile from chemotherapy or targeted therapy. The treatment with the anti-
PD-1 antibodies nivolumab and pembrolizumab and the anti-CTLA-4 antibody ipilimumab has improved survival in 
metastatic lung and renal cancer and in melanoma [26]. The raised immune response induced by these therapies has led to a 
specific group of side effects known as immune-related adverse events (irAEs), resulting from immune activation after the 
CTLA-4 and/or PD-1 inhibition [26], and can vary from mild to fatal, according to the organ system and severity [27].  
As ICI induce immune cells to attack normal tissues, every organ can be damaged, as skin, lungs, heart, muscles, bowels, 
liver, endocrine tissues, eyes, kidneys, and central nervous system [11, 28, 29]. According to clinical trial results about 7–
19% of patients treated with anti-PD-1/PD-L1 antibodies developed grade 3–5 adverse events. The discontinuation rate of 
ICI caused by adverse events ranged 3-8% for anti-PD-1/PD-L1 antibodies, and up to 15% for ipilimumab. The 
discontinuation rate due to adverse effects observed combining nivolumab and ipilimumab, is significantly higher (36% of 
rate) [8]. Of note, delayed toxicities can be observed months or even years after the last received dose of immune 
checkpoint inhibitor [11]. 
The most frequent ipilimumab-induced side effects involve gastrointestinal tract (colitis and diarrhoea), skin (pruritus and 
cutaneous rash), liver (autoimmune hepatitis) and endocrine system (hypophysitis and thyroid dysfunction). Immune-related 
arthritis, neuropathy, myositis, and uveitis happen occasionally [1].  
A systematic review and meta-analysis [30] was conducted on 81 articles, with a total of 1265 patients from 22 clinical 
trials to evaluate the incidence and nature of irAEs in oncologic patients administered with anti-CTLA-4 antibodies 
(ipilimumab and tremelimumab). The reported irAEs were skin lesions (rash, pruritus, and vitiligo); colitis; hepatitis, 
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hypophysitis, thyroiditis (less frequently); sarcoidosis, uveitis, Guillain-Barré syndrome, immune-mediated cytopenia and 
polymyalgia rheumatic/Horton (rarely). The overall incidence of all-grade irAEs was 72% (95% CI, 65–79%). The overall 
incidence of high-grade irAEs was 24% (95% CI, 18–30%). The risk of irAEs depended on the dosage, with incidence of 
all-grade irAEs being evaluated to 61% (95% CI, 56–66%) for ipilimumab 3 mg/kg and 79% (95% CI, 69–89%) for 
ipilimumab 10 mg/kg. About 0.86% of patients died owing to irAEs [30]. 
The safety profile of PD-1 blockade is similar and also includes pneumonitis of grade 1-2 [1]. Combination therapy did not 
cause new toxicities or deaths [1].  
 
4 Endocrine irAEs  
Immune-related endocrine toxicities are thyroid dysfunction, hypophysitis, adrenal insufficiency and type 1 diabetes 
mellitus (T1DM). In comparison to other irAEs, endocrinopathies are often irreversible manifestations [31], and papers 
show recovery of the pituitary–thyroid axis in up to 50% of patients [32] and in 50–60% for the pituitary–gonadal axis [32-
34], while few cases of corticotroph recovery have been described [33].  
Endocrine glands release hormones affecting cell function in a different location. The pituitary (or hypophysis), adrenal 
glands and thyroid are the endocrine organs that are usually affected by ICI. As the activity of the endocrine system is 
mediated by feedback loops among organ systems, the inflammation of a single gland causes the dysfunction of the affected 
organ and of downstream target organs [35]. Even if different systems can be affected simultaneously, a patient can have 
only thyroid or adrenal symptoms. Moreover, immune checkpoint blockade, and overall blockade of the PD-1/PD-L1 
pathway alone or combined with anti-CTLA-4, has also been associated with the onset of autoimmune T1DM [35].  
About the onset time of irAEs, it is usually from 7 weeks with ipilimumab and 10 weeks with nivolumab [36]. 
Endocrine irAEs have been reported in 0–29% of patients [37]. Ipilimumab-induced hypophysitis is the most frequent irAE 
grade 3/4; hypothyroidism and hyperthyroidism are next in frequency. Little is known for tremelimumab, that is associated 
with fewer reported endocrinopathies (0–8.3%) [37]. The incidence of endocrinopathies after the therapy with PD-1/PD-L1 
inhibitors is different from that with anti-CTLA-4 antibodies, as they have different mechanism of action. The induction of 
CTLA-4 in T cells occurs in the early stages of their response to antigens, while the PD-1/PD-L1 pathway regulates 
inflammatory reaction both in peripheral tissues and neoplastic microenvironment, and it is activated downstream of the 
immune response [37].  
The incidence of thyroid disorders as hypothyroidism, thyrotoxicosis, painless thyroiditis, or even ‘thyroid storm’ [33] is 
approximately 10% in patients administered with single agent anti-PD-1/PD-L1 [8, 38, 39], but also euthyroid Graves’ 
ophthalmopathy and other less common endocrine disorders have been described [40, 41]. 
 
4.1 Hypophysitis  
Hypophysitis related to anti-CTLA-4 therapy varies between 0.4-17% [32], and this variation could be due to differences in 
hormonal monitoring,  and drug dose.  
Combination of nivolumab with ipilimumab resulted in hypophysitis in about 8% of cases [26]. 
Anti-CTLA-4-related hypophysitis seems to be more common in men than in women [34], as for example one paper 
reported a prevalence of anti-CTLA-4-related hypophysitis of 3.6% in women and 15.6% in men [P=0.02; OR 4.73 (95% CI 
1.27–30.79)] [42], but these data are in contrast with idiopathic autoimmune hypophysitis, that has a men to women ratio of 
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1:3 [34]. This phenomenon is supposed to be caused by the increased melanoma prevalence in men in these trials [43].  
Regarding age, a retrospective review showed a significantly older population (mean age of 68.2±2.4 years with respect to 
59.9±1.0; P=0.005) with ipilimumab-related hypophysitis [42]. The review was conducted in 154 adult patients with 
metastatic melanoma and treated with ipilimumab between March 2008 and December 2013, and evaluated the prevalence 
of hypophysitis, the clinical course and treatment outcomes in hypophysitis, and identified the risk factors for the 
development of hypophysitis to define optimal strategies for its management [42]. The Authors concluded that male gender 
and older age are risk factors for hypophysitis [42]. 
Fatigue and/or muscle weakness and headache are present in 89% of patients diagnosed with hypophysitis, even if these 
symptoms are nonspecific [43]. Anorexia, nausea, weight loss, alterations in mental status, visual changes, temperature 
intolerance and arthralgias are described with a frequence of 10.5–21.1% [34]. Low levels of sodium (range 113-134 mEq/l) 
have been shown, too, in patients with anti-CTLA-4-related hypophysitis [34]. The morbidity linked to anti-CTLA-4-related 
hypophysitis seems to be associated with secondary adrenal insufficiency [27], that could be life threatening if not treated.  
Adrenocorticotropic hormone and/or thyroid stimulating hormone (TSH) deficiency are the most frequent pituitary hormone 
abnormalities in anti-CTLA-4-related hypophysitis patients, also low insulin-like growth factor 1 levels are present [34].  
 
4.2 Hyperglycaemia 
PD-1 pathway blockade can cause diabetes mellitus [44-47]. Anti-PD-1 therapy led to 8 cases of T1DM with another case 
in a patient administered with anti-PD-L1 therapy. Seven/9 T1DM patients had diabetic ketoacidosis and 2 patients had 
severe hyperglycemia [44-47]. GAD65 antibodies (T1DM marker) and diabetic ketoacidosis were present in 5 patients 
treated with nivolumab [44-47]. Three/5 patients had T1DM-specific autoantibodies (GAD65), and 40% the upregulation of 
CD8+ T-cell response to a T1DM antigen [45]. 
 
4.3 Adrenalitis 
Even if rarely, adrenalitis and following primary adrenal insufficiency caused by the therapy with ipilimumab have been 
shown [48, 49].  A 56-year-old woman with metastatic melanoma showed fatigue and headache after 4 doses of ipilimumab. 
Hypophysitis and secondary adrenal insufficiency were diagnosed for the presence of low morning cortisol and 
corticotropin levels and of pituitary enlargement. She started hydrocortisone. Bilateral enlargement of adrenal glands was 
shown by surveillance-computed tomography (CT) scan of the abdomen, while before the treatment with ipilimumab, her 
adrenal glands were normal in size. She did not respond to cosyntropin stimulation demonstrating primary adrenal 
insufficiency. Her adrenal glands normalized in size after 6 weeks, and this change in size of the adrenal glands indicates an 
ipilimumab-related autoimmune adrenalitis [48].  
In a 79-year-old imaging data of newly symmetrically and smoothly enlarged, hypermetabolic adrenal glands have been 
shown after ipilimumab therapy, indicating drug-induced adrenalitis and not metastatic disease [49].  
 
4.4 Thyroid disorders  
Thyroid abnormalities (as hypothyroidism, thyrotoxicosis, painless thyroiditis, or even “thyroid storm” [33]) are the second 
most common irAEs associated with anti-CTLA-4-antibodies [32] and are present in 1–6% of patients administered with 
ICI [33, 34].  
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In primary hypothyroidism, high TSH with low-to-normal free thyroxine (FT4) or triiodothyronine (T3) are present, while 
in hypothyroidism caused by pituitary dysfunction low to mid-normal levels of TSH with a low FT4 have been shown [34]. 
However, the measurement of T3 in patients with any acute illnesses could be not precise, and the best evaluation of 
primary thyroid dysfunction is TSH measurement [50]. 
In clinical trials conducted in patients administered with ipilimumab, the incidence of secondary hypothyroidism was 7.6% 
(4.3–11.0%), and primary hypothyroidism was shown in 5.6% of patients (5.2–5.9%) [34, 42, 51-61], even if data about the 
diagnostic test values, aetiology or management of hypothyroidism are not reported in most of these studies. 
A retrospective analysis of endocrine irAEs was conducted in 156 patients with melanoma treated with ipilimumab in 
clinical trials [43]. Pituitary-, thyroid-, and adrenal-related hormone tests, radiographic data and clinical history of patients 
were evaluated in order to identify cases of thyroiditis, adrenal dysfunction, hypophysitis, and hypothyroidism. The total 
incidence of hypophysitis was 8% and of hypothyroidism/thyroiditis 6%, while primary adrenal dysfunction was not 
frequent. The combined treatment with ipilimumab and nivolumab showed an incidence of 22% for either thyroiditis or 
hypothyroidism and 9% for hypophysitis [43]. 
Euthyroid Graves’ ophthalmopathy and other less frequent endocrine disorders were also observed [40, 41]. A study 
reported 3 patients with metastatic melanoma administered with ipilimumab alone or combined with bevacizumab, who 
developed thyroiditis, and euthyroid Graves' ophthalmopathy [40]. 
Thyroid disorders are the most frequent endocrine irAEs caused by tremelimumab (0%–5.2%), following a pattern similar 
to ipilimumab [62]. Graves’ hyperthyroidism was induced by tremelimumab in a 55-year-old man with metastatic 
melanoma after 8 years of treatment. The patient had no personal or family history of thyroid or autoimmune diseases. He 
was treated with carbimazole as block and replace therapy, with no complications, and the treatment with tremelimumab 
was temporarily discontinued and started again when he was euthyroid. Graves’ hyperthyroidism was not reported again 
since the discontinuation of block and replace therapy [63]. 
About 39.0-54.2% of patients treated with PD-1 antibodies show an immune related adverse event, too [34]. The most 
common endocrine adverse event with PD-1 antibody therapy was hypothyroidism (almost 5.9% of incidence), while 
hyperthyroidism in 1.0–4.7% of patients [34]. 
Ten patients showed painless thyroiditis syndrome after the therapy with anti-PD-1 monoclonal antibodies for metastatic 
malignancies [64]. Six patients had a transient thyrotoxicosis (with absence of thyrotropin binding inhibitory 
immunoglobulins), while 4 patients showed the presence of positive anti-thyroid antibodies. All thyrotoxic patients were 
administered with temporary beta-blockers and had spontaneous resolution of thyrotoxicosis and subsequently developed 
hypothyroidism. Four patients showed hypothyroidism without a preceding thyrotoxicosis, after 6-8 weeks from the 
beginning of the treatment. All the patients had positive anti-thyroid antibodies and were treated with a thyroid hormone 
replacement therapy for at least 6 months [64]. 
Another report showed a serological worsening of autoimmune thyroid disease in 2 patients treated with nivolumab, 1 with 
Hashimoto’s thyroiditis, and 1 with a probable subclinical Hashimoto’s thyroiditis [65]. 
Another case of nivolumab-induced painless thyroiditis was shown in a patient with no history of any thyroid disorders [66]. 
A 61-year-old man with no history of familial or personal thyroid disease with NSCLC was treated with radiotherapy and 
chemotherapy, and then, after the progression of cancer, with nivolumab [67]. After 3 infusions, the patient showed bilateral 
eyelid ptosis and bilateral conjunctival redness with chemosis. Ophthalmologic examination showed severe proptosis with 
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complete ophthalmoplegia, with normal thyroid function tests and without anti-thyroperoxidase or anti-TSH receptor 
antibodies. A strong bilateral proptosis with the expansion of the orbital adipose tissue, but no thickening of extraocular 
muscles, was shown by CT scan of the orbits. T2-weighted MRI showed inflammation of orbital adipose tissue. Nivolumab 
was withdrawn, and the patient treated with methylprednisolone (intravenously and once a week). After 3 cycles, a 
significant amelioration of left chemosis was observed. The patient died owing to massive hemoptysis, being euthyroid 
without thyroid autoimmunity 1 week prior to his death [67]. 
The case of a patient with metastatic squamous cell lung cancer who developed a symptomatic inflammatory myositis 
(confirmed with muscle biopsy and primary hypothyroidism), after nivolumab treatment, has been described. After 
initiation of corticosteroids and thyroid hormone replacement, there was an improvement of clinical and laboratory data 
[68].  
The combined treatment with nivolumab and ipilimumab caused the highest incidences of hypothyroidism (17%) and 
hyperthyroidism (10%) of any grade [38, 69]. 
Fifty-one patients with advanced NSCLC were treated with pembrolizumab as part of KEYNOTE-001 (NCT01295827) 
[70]. Thyroid function and anti-thyroid antibodies levels were evaluated prospectively at each study visit, starting before the 
first treatment. At baseline 3/51 patients were hypothyroid and 48/51 were not. Ten/48 [21%, 95% confidence interval (CI) 
10% to 35%] patients developed thyroid dysfunction and required thyroid replacement therapy. Eight/10 patients had anti-
thyroid antibodies and developed thyroid dysfunction, in comparison to 3/38 who did not (80% vs 8%, P<0.0001). During 
the treatment with pembrolizumab, thyroid dysfunction occurred early (median, 42 days), and 6/10 patients experienced a 
transient hyperthyroidism (before hypothyroidism) that was not persistent. Hyperthyroidism and hypothyroidism were both 
asymptomatic. Interestingly, OS with pembrolizumab was significantly higher in subjects who developed thyroid 
dysfunction (hazard ratio, 0.29; 95% CI 0.09-0.94; P=0.04) [70]. 
Accordingly another paper showed the appearance of thyroglobulin antibodies (TgAbs) and was associated with prolonged 
survival [71]. The development of TgAbs was evaluated in patients treated with GVAX [a cancer vaccine constituted by 
whole tumor cells genetically modified to secrete the immune stimulatory cytokine, granulocyte-macrophage colony-
stimulating factor (GM-CSF), and then irradiated to prevent further cell division] and/or ipilimumab and correlated TgAbs 
seroconversion with survival. TgAbs were evaluated in patients with pancreatic (n=53), prostate (n=35) or colon (n=8) 
cancer, before and after the treatment with GVAX alone (n=34), or combined with ipilimumab (n=42) or ipilimumab alone 
(n=20). TgAbs developed after GVAX, independently from the type of cancer (75% colon cancer, 76% pancreatic cancer 
and 81% in prostate) and co-administration of ipilimumab (75% in GVAX alone, and 78% if combined with ipilimumab). 
Of note, TgAbs seroconversion was associated with significantly prolonged survival (P=0.01 for pancreas and P=0.005 for 
prostate cancer) [71]. 
A prospective study [72] was conducted between April 2014 and October 2015, in 177 patients with metastatic melanoma 
administered with: 1. ipilimumab (n=15); 2. anti-PD-1 (nivolumab, pembrolizumab) (n=103); 3. a combination of 
ipilimumab and anti-PD-1 (n=59). The presence of endocrinopathies was then evaluated in these patients. Thirty-one 
patients (18%) developed an endocrine irAE (14%, thyroid dysfunction; 6%, hypophysitis; 0.6%, autoimmune diabetes). 
Combination immunotherapy more frequently resulted in a single or multiple endocrinopathy in comparison to anti-PD-1 
monotherapy (27% vs 9% and 7% vs 0% respectively, P<0.01). Endocrinopathies occurred after a median of 8 weeks from 
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the beginning of treatment, with a significantly earlier onset in comparison to the treatment with ipilimumab alone (median: 
30 vs 76 days, P=0.046) [72].  
 
5 Management of thyroid disorders 
The Society for Immunotherapy of Cancer (SITC) has recently established a multidisciplinary Toxicity Management 
Working Group, to develop consensus guidelines to evaluate and manage toxicities associated with ICI [73]. Then, the 
American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) published 
clinical practice guidelines on the management of ICI toxicities [74, 75]. 
Clinical signs and symptoms vary according to the influenced target organ. Thyroid disorders are usually asymptomatic and 
are monitored by routine laboratory tests, even if sore throat, other symptoms of hyperthyroidism, tachycardia and 
palpitations, can be present in the case of thyroiditis [35]. 
Endocrinopathies can often be managed by the treating oncologist. In more severe cases (i.e. in the presence of insulin-
dependent diabetes, adrenal insufficiency, or disorders of gonadal hormones, or for long-lasting management of 
hypophysitis) an endocrinologist should be considered [35]. 
The treatment algorithms are useful to manage ICI-related endocrinopathies, but also the clinical experience of physicians 
are determinant. In the case of asymptomatic TSH abnormalities, if TSH is <0.5 x lower limit of normal (LLN) or >2 x 
upper limit of normal (ULN), FT4 levels should be evaluated. According to the clinical presentation, it could be necessary 
to assess the cortisol level besides FT4 and T3. Thyroid hormone replacement therapy is started when FT4 levels fall 
beneath normal range and can be changed as required, usually starting with 50 mcg of levothyroxine, excluding a possible 
contemporaneous adrenal insufficiency by a cortisol level dosage [35]. 
During treatment with ICI, thyroid function should be evaluated at baseline and next every 2 months [8, 76]. ICI can be 
carried on for grade 1–2 hyperthyroidism, and the therapy is started in the case of hyperthyroidism symptoms [77, 78]. If 
hyperthyroidism is symptomatic (grade 3), ICI should be stopped and corticosteroids begun (oral prednisolone 1–2 
mg/kg/day) [77]. From necessity, anti-thyroid drugs (propilthyouracil, methimazole, or carbimazole) may be recommended. 
In case of severe hyperthyroidism (grade 4), ICI should be stopped at all, and methylprednisone (1–2 mg/kg/day; IV; for 3 
days) and then oral prednisolone (1–2 mg/kg/day) should be administered. Prednisolone is then decreased over at least 1 
month [77]. Beta-blockers can be used to treat hyperthyroidism symptoms, as tachycardia and tremor. Steroids should be 
administered if the patient is very symptomatic [26]. 
To evaluate the pathogenesis of hyperthyroidism, thyroid ultrasound and vascularization should be evaluated, in fact, 
hypervascularity is associated with Graves’ disease, while hypovascularity with destructive thyroiditis [8]. 
In the course of treatment thyroid function should be regularly monitored to permit the early detection of hypothyroidism, 
and in the case the patient is already symptomatic, the clinical state should be evaluated to decide whether ICI should be 
stopped [33, 77, 79]. 
 
6 Conclusion 
The immune system recognizes and destroys tumor cells, through the antigens recognition by T-cells. Cancer therapies lead 
cancer cells to die and release tumor antigens, presented by dendritic cells in the tumor-draining lymph nodes in order to 
activate tumor immunity. In this way, tumor-specific T cells enter the circulation towards tumors, infiltrating the tumor 
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mass. Cancer cells lysis, mediated by T-cells, leads to a higher release of tumor antigens, perpetuating the cycle [8]. 
However cancers inhibit “immune checkpoints” during tumor progression, suppressing the immune response. 
ICI are drugs that inhibit the “inhibitory checkpoint molecules”. Different types of cancer immunotherapies have been 
approved recently: CTLA-4 monoclonal antibodies (as ipilimumab); anti-PD-1 monoclonal antibodies (as pembrolizumab 
and nivolumab); and anti-PD-L1 monoclonal antibodies (as atezolizumab, avelumab, and durmalumab). 
The increased immune response induced by these agents leads to irAEs, that can vary from mild to fatal, according to the 
organ system and severity [27]. Immune-related endocrine toxicities by ICI include thyroid dysfunction, hypophysitis, 
adrenal insufficiency and T1DM, and are usually irreversible, with studies showing recovery of the pituitary–thyroid axis in 
up to 50% of patients, and in 50–60% for the pituitary–gonadal axis. For this reason, immune-related endocrine toxicities 
need to be immediately recognized, and appropriately treated [8]. 
Of note, the appearance of anti-thyroid autoantibodies, thyroiditis, or thyroid dysfunction, in patients treated with ICI has 
been associated with a prolonged survival [71, 80], leading to hypothesize that these could be markers of a more potent 
immune activation. This could be investigated also in other cancer patients (not only with thyroid cancer).  
The induction of an autoimmune reaction could be assessed also in other types of cancer showing specific antigens, or 
overexpressing an antigen (i.e. calcitonin, or precursor protein preprocalcitonin in medullary thyroid cancer, or 
carcinoembryonic antigen in colon cancer, etc.), in association with ICI therapy.  
Consensus guidelines to evaluate and manage irAEs associated with ICI have been recently published [73-75]. 
Clinical signs and symptoms vary according to the influenced target organ. Endocrinopathies can often be managed by the 
treating oncologist. However in more severe cases (i.e. in the presence of insulin-dependent diabetes, adrenal insufficiency, 
or disorders of gonadal hormones, or severe hyperthyroidism, or hypothyroidism, or for long-lasting management of 
hypophysitis) an endocrinological evaluation, and a prompt therapy, are needed [35].  
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